References

1. Staats PS. Complications of intrathecal therapy. Pain Medicine. 2008;9(suppl_1):S102-S7.
2. Simpson KH, Jones I. Intrathecal drug delivery for management of cancer and noncancer pain. Journal of opioid management. 2008;4(5):293-304.
3. Cabbell KL, Taren JA, Sagher O. Spinal cord compression by catheter granulomas in high-dose intrathecal morphine therapy: case report. Neurosurgery. 1998;42(5):1176-80.
4. Miele VJ, Price KO, Bloomfield S, Hogg J, Bailes JE. A review of intrathecal morphine therapy related granulomas. European journal of pain. 2006;10(3):251-61.
5. Arnold PM, Harsh V, Oliphant SM. Spinal cord compression secondary to intrathecal catheter–induced granuloma: a report of four cases. Evidence-based spine-care journal. 2011;2(1):57.
6. Amir-Hadi Maghzi ME, Mohammad-Reza Savoj, J. Steven Alexander, Eduardo Gonzalez-Toledo, Alireza Minagar,. 10 - Transverse Myelitis. 2011:225 - 35.
7. Ubogu EE, Lindenberg JR, Werz MA. Transverse myelitis associated with Acinetobacter baumanii intrathecal pump catheter-related infection. Regional Anesthesia & Pain Medicine. 2003;28(5):470-4.
8. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. International Journal of Radiation Oncology* Biology* Physics. 1992;23(1):9-17.
9. Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. Journal of Clinical Oncology. 2016;34(26):3150-6.
10. Ferreri AJ, Blay J-Y, Reni M, Pasini F, Spina M, Ambrosetti A, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. Journal of Clinical Oncology. 2003;21(2):266-72.
11. Poulain S, Boyle EM, Tricot S, Demarquette H, Doye E, Roumier C, et al. Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma. British journal of haematology. 2015;170(2):285.
12. McKay P, Wilson MR, Chaganti S, Smith J, Fox CP, Cwynarski K, et al. The prevention of central nervous system relapse in diffuse large B‐cell lymphoma: a British Society for Haematology Good Practice Paper. British Journal of Haematology. 2020.
13. Ellison D, Wilkins B. Lymphoma and the nervous system. Neuropathology: Springer; 2001. p. 239-65.